Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 18Neoplasm Metastasis 14Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Recurrence 9Ovarian Neoplasms 7Skin Neoplasms 6Head and Neck Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Renal Cell 5Carcinoma, Basal Cell 5Triple Negative Breast Neoplasms 4Fallopian Tube Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Merkel Cell 3Adenocarcinoma 3Sarcoma 2Pancreatic Neoplasms 2Lymphoma 2Lung Neoplasms 2Glioma 2

Interventions

Dexamethasone 307Bortezomib 161Lenalidomide 130pomalidomide 112daratumumab 94carfilzomib 69Calcium Dobesilate 41Cyclophosphamide 40belantamab mafodotin 31elotuzumab 30fludarabine 27ixazomib 23isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Multiple Myeloma × cemiplimab × Clear all
NCT05669989 2026-05-11

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Sanofi

Phase 2 Active not recruiting
70 enrolled
Plasma cell

Multiple Myeloma

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Regeneron Pharmaceuticals

Phase 1 Recruiting
317 enrolled
Plasma cell

Multiple Myeloma

NCT03194867 2024-06-14

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Sanofi

Phase 1/2 Completed
109 enrolled 27 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡